Matinas Biopharma Holdings, Inc.

Stage 2 · Advancing · week 3

As of Oct 22, 2026, Matinas Biopharma Holdings is in Stage 2, the uptrend phase, now in week 3 (since Oct 8, 2026). It closed at $1.71, 43.2% below its 52-week high and above its 200-day average, which is rising.

$1.71

+23.75% today

$1.7M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is MTNB early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 49w

S2 14w

S4 21w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 11w → S1 9w → S4 7w → S1 5w → S2 4w → S3 4w → S4 49w → S1 12w → S2 14w → S3 7w → S4 21w → S1 8w → S4 10w → S1 1w → S2 2w current

Total tracked: 165 weeks across 15 stage runs.

MTNB among Biotechnology179th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…179	MTNBMatinas Biopharma Holdings, Inc.	Stage 2 · wk 3	57	+877.1%

vs 52W High

-43.2%

$0.16 lo$3.01 hi

43.2% below 52W high

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 3

1w13w26w

Week 3, fresh breakout

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

145.0%

200 DMA: $0.70 · rising

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.06x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↑

Short-term trend rising strongly

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+877.1%

+609.5%

+177.1%

YTD

+175.8%

+3.6%

Scan Membership

Breakout Watch

Latest: 2024-04-02

7 appearances in last 60 days. First seen: 2018-11-05.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 3 · Vol 0.06x

2026-10-21S2

Wk 2 · Vol 0.03x

2026-10-20S2

Wk 2 · Vol 0.06x

2026-10-19S2

Wk 2 · Vol 0.33x

2026-10-16S2

Wk 2 · Vol 0.03x

2026-10-15S2

Wk 2 · Vol 0.02x

2026-10-14S2

Wk 1 · Vol 0.02x

2026-10-13S2

Wk 1 · Vol 0.07x

2026-10-12S2

Wk 1 · Vol 0.02x

2026-10-09S2

Wk 1 · Vol 0.03x

2026-10-08S21→2

Wk 1 · Vol 0.08x

2026-10-07S1

Wk 1 · Vol 0.09x

Moving averages & range

50 DMA

$1.04

200 DMA

$0.70

52W High

$3.01

52W Low

$0.16

5D Low

$1.38

Resistance levels (recent highs)

20d High

$3.01

60d High

$3.01

120d High

$3.01

250d High

$3.01

Next resistance

+76.0%

to 20d High

ROE

-141.2%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.4

Matinas Biopharma Holdings: quick answers

What stage is Matinas Biopharma Holdings in?

As of Oct 22, 2026, Matinas Biopharma Holdings (MTNB) is in Stage 2, the uptrend phase. It entered Stage 2 on Oct 8, 2026 and is in week 3. What the four stages mean

Is Matinas Biopharma Holdings in an uptrend?

Yes. Matinas Biopharma Holdings is in a Stage 2 uptrend. It trades 145.0% above its 200-day average, which is rising.

How far is Matinas Biopharma Holdings from its 52-week high?

Matinas Biopharma Holdings closed at $1.71 on Oct 22, 2026, 43.2% below its 52-week high of $3.01. Its 52-week low is $0.16.

How has Matinas Biopharma Holdings performed over the past year?

As of Oct 22, 2026, Matinas Biopharma Holdings is up 3.6% over the past year and up 175.8% so far in 2026.

Which sector and industry is Matinas Biopharma Holdings in?

Matinas Biopharma Holdings is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company was incorporated in 2013 and is based in Bedminster, New Jersey.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.